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اجلوانب السريرية )اإلكلينيكية(، حتليل النمط املناعي الظاهري ومعدل البقاء على 
قيد احلياة ملرضى سرطان الدم الليمفاوي املزمن يف مدينة أربيل، العراق
كاوه حممدامني ح�شن
abstract: Objectives: Chronic lymphocytic leukaemia (CLL) is characterised by an accumulation of clonal B cells 
in the blood, bone marrow and lymphatic tissue. This study aimed to evaluate the clinical and immunophenotypic 
characteristics and survival rate of CLL patients. Methods: This retrospective study was conducted at the Nanakaly 
Hospital for Blood Diseases & Oncology in Erbil, Iraq, between January 2011 and December 2017. A total of 105 
CLL patients were assessed to determine clinical presentation and staging, immunophenotype and survival rate. 
Results: The median age of the patients was 65 years and 63.8% were male. The main clinical presentations were 
splenomegaly (64.8%), pallor (61.9%) and lymphadenopathy (60%). More than half of the patients presented at an 
advanced clinical stage according to the Rai and Binet staging systems (59.1% and 55.2%, respectively). All CLL 
cases expressed both cluster of differentiation (CD)19 and CD5, 67.6% had monoclonal kappa light chains and 
21% expressed CD38. The five-year overall survival (OS) rate was 61.3%. The mean duration of five-year survival 
was 41.3 months (95% confidence interval: 36.4–46.3 months). There were no correlations between survival and 
sociodemographic, clinical or laboratory characteristics. Conclusion: In comparison to the existing Western 
literature, Iraqi CLL patients more frequently presented with hepatosplenomegaly and at a more advanced clinical 
stage. In addition, the five-year OS rate was much lower.
Keywords: Lymphoproliferative Disorders; Chronic Lymphocytic Leukemia; Immunophenotyping; Survival Rates; 
Iraq.
هدفت  الليمفاوي.  والن�شيج  العظام  ونخاع  الدم  يف  الن�شيلة  ب  خاليا  برتاكم  املزمن  الليمفاوي  الدم  �رصطان  يتميز  الهدف:  امللخ�ص: 
هذه الدرا�شة ايل تقييم اخل�شائ�س ال�رصيرية و النمط املناعي الظاهري ومعدل البقاء على قيد احلياة للمر�شى امل�شابني ب�رصطان الدم 
الليمفاوي املزمن. الطريقة: اأجريت هذه الدرا�شة الأ�شرتجاعية يف م�شت�شفى ناناكايل لأمرا�س الدم والأورام يف اأربيل، العراق، بني يناير 
2011 ودي�شمرب 2017. مت تقييم ما جمموعه 105 م�شابا مبر�س �رصطان الدم الليمفاوي املزمن لتحديد العر�س ال�رصيري و مرحلة املر�س 
%63.8 من الذكور. وكانت  65 �شنة بينهم  و النمط املناعي الظاهري ومعدل البقاء على قيد احلياة. النتائج: كان متو�شط عمر املر�شى 
العالمات ال�رصيرية الرئي�شية عبارة عن ت�شخم الطحال )%64.8(، �شحوب )%61.9( واعتالل العقد اللمفاوية )%60(. كان اأكرث من ن�شف 
املر�شى يف مرحلة �رصيرية متقدمة وفقا جلداول راي وبينيت )%59.1 و %55.2 على التوايل(. اأظهر حتليل النمط املناعي الظاهري جلميع 
املر�شى كال من جمموعة التمايز 19 و 5، بينما اأظهر %67.6 من املر�شى �شال�شل كابا اخلفيفة وحيدة الن�شيلة و %21 منهم كان لديهم 
جمموعة التمايز 38. وكان املعدل العام للبقاء على قيد احلياة ملدة خم�س �شنوات هو %61.3. وكان متو�شط مدة البقاء على قيد احلياة 
اأ�شهر(. مل تكن هناك ارتباط بني معدل البقاء على قيد احلياة وال�شفات   46.3–36.4 :95% 41.3 �شهرا )فا�شل الثقة  ملدة خم�س �شنوات 
الجتماعية والدميوغرافية وال�رصيرية واملخربية للمر�شى. اخلال�صة: باملقارنة مع املطبوعات الغربية احلالية، فاإن مر�شى �رصطان الدم 
الليمفاوي املزمن العراقيني لديهم بن�شبة اكرث من ت�شخم الطحال والكبد ويتم ت�شخي�شهم يف مرحلة �رصيرية اأكرث تقدًما. بالإ�شافة اإىل 
ذلك، كان معدل البقاء على قيد احلياة ملدة خم�س �شنوات فيهم اأقل بكثري.
الكلمات املفتاحية: ال�شطرابات التكاثرية الليمفاوية؛ �رصطان الدم الليمفاوي املزمن؛ النمط املناعي الظاهري؛ معدلت البقاء على قيد احلياة؛ العراق.
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Advances in Knowledge
- This study provides the clinical and immunophenotypic findings and the survival rate of chronic lymphocytic leukaemia (CLL) patients in Erbil 
City, Iraq. 
- The current sample of CLL patients more frequently presented with hepatosplenomegaly, although less frequently with lymphadenopathy, 
compared to populations reported from Western countries. In addition, the Iraqi patients tended to present at a more advanced clinical stage and 
had lower survival rates than Western patients.
Application to Patient Care
- The current results highlight the importance of implementing more advanced work-up tools for Iraqi CLL patients, such as a thorough cytogenetic 
evaluation.
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Chronic lymphocytic leukaemia (cll) is the most common type of leukaemia among adults in Western countries; however, it is relat- 
ively rare in Asia.1,2 It is characterised by the build-up of 
lymphocytes in the blood, bone marrow and lymphatic 
tissue. The median age at diagnosis ranges from 67–72 
years and the condition is more common in males.1,2 
The clinical course of CLL is highly variable, ranging 
from no symptoms to the rapid development of features 
of high-risk disease.3 Lymph node swelling is the most 
common presenting feature of CLL, although fever, night 
sweats and weight loss are sometimes seen. The most 
common physical findings are lymphadenopathy, splen- 
omegaly and, less frequently, hepatomegaly.3
A diagnosis of CLL can be established via a complete 
blood count (CBC) showing the progressive accumulation 
of clonal B cells (>5,000 B lymphocytes/mL) over a period 
of at least three months and an immunophenotypic study 
demonstrating clonal lymphocytes expressing B cell mar- 
kers and cluster of differentiation (CD)5.4 Both the mod- 
ified Rai and Binet clinical staging systems are widely 
used to classify CLL patients into different prognostic 
groups according to the extent of lymph node involve-
ment, enlargement of the liver and/or spleen and blood 
findings (i.e. anaemia and thrombocytopaenia).5,6
The median survival rate for patients with CLL 
ranges from 18 months to more than 10 years, depending 
on prognostic factors like age, gender, disease stage, 
performance status, lymphocyte doubling time, absolute 
lymphocyte count (ALC) and β-2 microglobulin serum 
levels.7 Furthermore, the expression of certain biological 
markers such as CD38 or CD49d, deletion of chromo- 
some 17p13 and the mutation status of the immuno-
globulin heavy-chain variable region, tumour protein- 
53 (TP53), Notch homolog 1, splicing factor-3B subunit-1 
(SF3B1), baculoviral inhibitor of apoptosis protein-1 
repeat-containing protein-3 (BIRC3), myeloid different- 
iation primary response 88 and zeta chain T cell receptor- 
associated protein kinase-70 (ZAP70) genes also have 
a prognostic impact.8 The current study aimed to assess 
and compare the clinical characteristics, immunopheno- 
typic findings and survival rate of CLL patients in 
Erbil, Iraq, with previously reported international and 
regional data.
Methods
This retrospective study was carried out between January 
2011 and December 2017 at the Nanakaly Hospital for 
Blood Diseases & Oncology, a regional referral hospital 
for adult and paediatric patients with benign and malig- 
nant haematology and solid oncology disorders in Erbil, 
Iraq. All patients attending the hospital during the study 
period and diagnosed with CLL as confirmed by CBC 
and immunophenotyping were invited to participate 
in the study. 
The main clinical presentation and characteristics 
of each patient was documented, including the presence 
of lymphadenopathy, pallor, hepatomegaly and spleno- 
megaly. In addition, the patients underwent a CBC 
and immunophenotyping study by flow cytometry using 
a FACSCanto II flow cytometer device (BD Biosciences, 
San Jose, California, USA) and/or immunohistochemistry. 
The laboratory analysis included a reticulocyte count, 
erythrocyte sedimentation rate, direct antiglobulin test 
(DAT), bone marrow examination, serology tests (i.e. 
to determine lactate dehydrogenase [LDH] levels) and 
liver and renal function tests. In indicated cases, patients 
also underwent various imaging studies, including ultra- 
sonography of the abdomen, a chest X-ray and computed 
tomography. In each case, clinical stage was determined 
Table 1: Baseline characteristics of chronic lymphocytic 

























*Percentages do not add up to 100% as some patients may have had 
more than one clinical presentation. †For patients with splenomegaly, 
the mean longitudinal axis of the spleen was 14.7 ± 3.4 cm.
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according to both the Rai and Binet staging systems.5,6 
Survival rates were calculated, including the overall 
survival (OS) rate over the study period and the five-
year OS rate. 
Data were analysed using the Statistical Package 
for the Social Sciences (SPSS), Version 22.0 (IBM Corp., 
Armonk, New York, USA). A Chi-squared test was used 
to compare associations between proportions. Kaplan-
Meier survival curves were plotted and the log-rank 
Mantel-Cox test was used to compare mean survival 
times. A P value of ≤0.050 was considered statistically 
significant.
This study was approved by the Scientific and 
Ethical Committees of the College of Medicine, Hawler 
Medical University, Erbil. 
Results
A total of 143 CLL patients attended the hospital during 
the study period. However, 38 patients were excluded 
due to a lack of adequate data or follow-up. As such, 
 
Figure 1: Immunophenotypic findings of chronic lymphocytic leukaemia patients in Erbil, Iraq (N = 105).
CD = cluster of differentiation; Bcl2 = B cell lymphoma 2; FMC7 = Flinder Medical Centre-7.
Table 2: Laboratory results of chronic lymphocytic leukaemia patients in Erbil, Iraq (N = 105)
Investigation Mean ± SD Median Range Normal range
Haemoglobin in g/dL 10.6 ± 2.3 11 5–15.4 13.5–17.5/11.5–15.5*
Whole blood count × 109/L 94.8 ± 106.6 65 8.9–491 4–11
Absolute lymphocyte count × 109/L 87 ± 104.5 58.5 6–462.5 1–4.8
Absolute neutrophil count × 109/L 6.7 ± 5.7 6 0.2–54 1.8–7.7
Platelet count × 109/L 140 ± 74.2 115 30–382 150–400
Reticulocytes, % 2.1 ± 2.0 1.7 0.1–10 0.5–1.5
Erythrocyte sedimentation rate in mm/hour 44.3 ± 33.3 37 2–145 0–10/3–15*
Lactate dehydrogenase in U/L 400.1 ± 159.9 378 108–905 100–250
Aspartate aminotransferase in U/L 24 ± 10.9 22 8.9–99 8–48
Alanine transaminase in U/L 18.1 ± 9.9 17 4–50.3 7–55
Blood urea in mg/dL 44.2 ± 21.3 41 16.3–160 15–40
Serum creatinine in mg/dL 1 ± 0.4 1 0.3–3 0.7–1.3
SD = standard deviation. *Males/females.
Table 3: Treatment provided to chronic lymphocytic 






Chlorambucil plus prednisolone 10 (9.5)
Rituximab and chlorambucil 10 (9.5)
COP 4 (3.8)
Rituximab and COP 5 (4.8)
Rituximab and CHOP 7 (6.7)
Rituximab 2 (1.9)
No treatment 17 (16.2)
FCR = fludarabine, cyclophosphamide and rituximab; BR = bendam-
ustine plus rituximab; FC = fludarabine plus cyclophosphamide; COP = cyclo- 
phosphamide, oncovin and prednisolone; CHOP =cyclophosphamide, hydro- 
xydaunomycin, oncovin and prednisolone. *Percentages do not add up to 
100% as four patients were treated with more than one protocol. 
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105 patients were included in the final analysis. Of 
these, 67 (63.8%) were male and 38 (36.2%) were 
female. The mean age at presentation was 63.3 ± 10.7 
years. Most patients (70.5%) were ≥60 years, with 
only 9.5% <50 years. The age at diagnosis ranged 
from 28–81 years old, with a median of 65 years. The 
main clinical presentations were splenomegaly (64.8%) 
pallor (61.9%) and lymphadenopathy (60%). Hepatomegaly 
was observed in 21.9% of patients. Modified Rai staging 
showed a high risk (stage III or IV) of CLL in 59.1%, an 
intermediate risk (stage I or II) in 27.6% and a low risk 
(stage 0) in 13.3% of patients. In terms of Binet staging, 
55.2% of patients were stage C, 17.1% were stage B and 
27.6% were stage A [Table 1]. Most patients (72.4%) 
were from Erbil and other cities in the Kurdistan region 
of Iraq, while the rest were from other northern and 
western Iraqi cities. 
The mean haemoglobin level was 10.6 ± 2.3 g/dL 
(range: 5–15.4 g/dL). Mean platelet and white blood cell 
counts were 140 ± 74.2 × 109/L (range: 30–382 × 109/L) 
and 94.8 ± 106.6 × 109/L (range: 8.9–491 × 109/L), 
respectively. The mean ALC was 87 ± 104.5 × 109/L 
(range: 6–462.5 × 109/L) [Table 2]. Overall, LDH levels 
were elevated in 82.8% of patients and 11.4% had 
autoimmune haemolytic anaemia (AIHA) with positive 
DAT results. Anaemia was observed in 83 (79.1%) patients, 
comprising 83.6% and 71.1% of male and female patients, 
respectively. A total of 63 (60%) and 28 (26.7%) patients 
presented with thrombocytopaenia and incidental lymph- 
ocytosis, respectively. None of the patients had Richter’s 
syndrome.
All patients underwent immunophenotyping an- 
alysis via flow cytometry and/or immunohistochemistry 
from either peripheral blood (79.1%) or bone marrow 
(21%) samples. All cases expressed both CD19 and CD5, 
while the vast majority expressed CD23 (94.3%), CD45 
(84.8%) and B cell lymphoma 2 (82.9%). About two-
thirds of the patients (67.6%) expressed monoclonal 
kappa light chains, while just under one-third (32.4%) 
expressed lambda chains. Only 21% of cases expressed 
CD38 [Figure 1]. In terms of treatment, most patients 
received either fludarabine, cyclophosphamide and 
rituximab (22.9%) or bendamustine plus rituximab (18.1%). 
The rest underwent various other chemotherapy prot-
ocols (46.7%) or did not receive any treatment at all 
(16.2%) [Table 3].
The mean follow-up period was 27.7 months. A 
total of 34 (32.4%) patients died during the study period, 
of which 24 (70.6%) were male and 10 (29.4%) were 
female, resulting in an OS rate of 67.6%. Although 
survival was greater among those aged 50–59 years 
(90.5% versus 60–62.5% in other age groups) and among 
females (73.7% versus 64.2% in males), these differences 
were not statistically significant (P = 0.098 and 0.163, 
Table 4: Correlation between survival rate and selected 
characteristics among chronic lymphocytic leukaemia 
patients in Erbil, Iraq (N = 105)






<50 6 (60) 4 (40)
0.098
50–59 19 (90.5) 2 (9.5)
60–69 25 (62.5) 15 (37.5)
≥70 21 (61.8) 13 (38.2)
Gender
Male 43 (64.2) 24 (35.8)
0.163
Female 28 (73.7) 10 (26.3)
Lymphadenopathy
Yes 41 (65.1) 22 (34.9)
0.496
No 30 (71.4) 12 (28.6)
Splenomegaly
Yes 46 (67.6) 22 (32.4)
0.993
No 25 (67.6) 12 (32.4)
Hepatomegaly
Yes 14 (60.9) 9 (39.1)
0.434
No 57 (69.5) 25 (30.5)
Rai clinical stage
0 12 (85.7) 2 (14.3)
0.190
I 4 (44.4) 5 (55.6)
II 15 (75) 5 (25)
III 14 (73.7) 5 (26.3)
IV 26 (60.5) 17 (39.5)
Binet clinical stage
A 21 (72.4) 8 (27.6)
0.648B 13 (72.2) 5 (27.8)
C 37 (63.8) 21 (36.2)
Hb level in g/dL
≤11 54 (65.9) 28 (34.1)
0.465
>11 17 (73.9) 6 (26.1)
WBC × 109/L
<65 37 (69.8) 16 (30.2)
0.628
≥65 34 (65.4) 18 (34.6)
Platelet count × 109/L
<150 44 (69.8) 19 (30.2)
0.551
≥150 27 (64.3) 15 (35.7)
LDH in U/L
<250 17 (81) 4 (19)
0.144
≥250 54 (64.3) 30 (35.7)
Hb = haemoglobin; WBC = white blood cells; LDH = lactate 
dehydrogenase.
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respectively). Other clinical and laboratory characteristics 
were also not significantly correlated with survival 
(P >0.050 each) [Table 4]. The five-year OS rate was 
61.3%. The mean duration of five-year survival was 60 
months (95% confidence interval: 36.4–46.3 months); 
however, the median survival could not be estimated 
and could have occurred beyond the study period. The 
mean duration of survival was longer among females 
and those aged 50–59 years old; however, these 
differences were not statistically significant (P = 0.185 
and 0.163, respectively) [Figure 2]. 
Discussion
In the current study, the median age at diagnosis of 
CLL patients in Erbil, Iraq, was similar to that reported 
in neighbouring countries such as Iran and Turkey 
(65 years versus 60.73 and 64 years, respectively).2,9 
In contrast, the median age at diagnosis in Western 
countries is much higher, ranging from 67–72 years 
old.1,10,11 However, the frequency of male CLL patients 
in the current study was identical to that reported in 
Italy (64%).12 In terms of clinical presentation, spleno-
megaly (64.8% versus 54%) and hepatomegaly (21.9% 
versus 14%) were reported more frequently in the 
current study compared to Western patients, while 
lymphadenopathy was less frequent (60% versus 
87%).3 In Turkey, rates of splenomegaly, hepatomegaly 
and lymphadenopathy differed at 55.4%, 54.6% and 
79.2%, respectively.9 In Iran, Payandeh et al. also reported 
varying rates of organomegaly (34%) and lymphaden-
opathy (38.7%).2 The diversity of clinical presentations 
in CLL and correlations with ethnicity have been well 
documented in previous research.13
The incidence of anaemia and AIHA in the 
current study (78.1% and 11%, respectively) was comp- 
arable to that reported in previous research in which 
AIHA was documented in up to 11% of late-stage CLL 
patients, with positive DAT results seen in up to 15% 
of patients.14 In the present study, 60% of patients had 
thrombocytopaenia; this finding is understandable 
given that most patients presented at an advanced 
clinical stage, such as Rai stage III or IV (59.1%) or 
Binet stage C (55.2%). According to data from other 
developing countries such as Iran, Turkey and India, 
patients in this region are often first seen at more 
advanced stages (38.5%, 33.3% and 41%, respectively).2,15,16 
However, in developed countries, only 10–20% of patients 
present at an advanced stage.17 These findings may 
indicate that routine CBC analysis is less frequently 
performed in developing countries or that hospitals 
in this region lack proper evaluation and management 
protocols or experience delays in the referral of patients 
with incidental lymphocytosis. It is also possible that 
there is a difference in the biology of the disease (e.g. in 
terms of such patients having a less mutated subtype 
of CLL).4
In the present study, most cases expressed CD19, 
CD5 and CD23, with CD79b less frequently expressed; 
these findings are consistent with the characteristic 
profile of CLL disease.18 For those patients not expressing 
CD23—considered atypical CLL cases—other markers 
could help to differentiate CLL from mantle cell lymph- 
oma, such as the negative expression of Flinder Medical 
 
Figure 2: Kaplan-Meier survival curves showing (A) five-
year overall survival (OS), (B) five-year OS by age group 
(P = 0.185) and (C) five-year OS by gender (P = 0.163) 
among chronic lymphocytic leukaemia patients in 
Erbil, Iraq (N = 105).
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Centre-7.19 Overall, CD38 expression at any level 
is regarded as a poor prognostic indicator; it was 
expressed in 21% of cases in the present study, which 
is comparable to the findings of Hojjat Farsangi et al. 
(27.6%).20 In the current study, 67.6% of patients had 
monoclonal kappa light chains, with 32.4% expressing 
lambda chains. Hojjat Fersangi et al. reported rates of 
expression of kappa and lambda chains to be 71.3% 
and 28.7%, respectively, among Iranian CLL patients.20 
Stamatopoulos et al. also reported similar findings in 
Greece.21
The OS (67.6%) in the current study was comp-
arable to data reported from Iran (64%), although 
the five-year OS rate (61.3%) was higher than 
results from Turkey (36.5%) and India (51%).2,22,23 
However, data from Germany and the USA indicate 
much higher five-year relative survival rates (80.2% and 
82.4%, respectively).24 The mean duration of five-year 
survival in the current study was 41.3 months, which 
is similar to data reported from Iran (38.5 months).2 
This may be related to variations in a number 
of patient-related characteristics, such as clinical 
stage at diagnosis. The reason why the five-year OS rate 
in the present study was lower than the overall OS is 
likely because patients whom were more recently 
diagnosed (i.e. in 2015–2017) had not yet received 
their five-year follow-up at the time of the analysis.
Early diagnosis plays a major role in improving 
survival in CLL patients.25 Other possible causes for 
low five-year OS rates are the lack of availability of 
equipment to conduct thorough cytogenetic evaluations 
for factors known to have a prognostic impact—such as 
deletions of chromosomes 11q, 13q, 17p and trisomy 
12 as well as TP53, NOTCH1, SF3B1 and BIRC3 gene 
mutations.8 In addition, insufficient access to adequate 
or novel chemotherapy agents like obinutuzumab, ibru- 
tinib, idelalisib and venetoclax as a frontline treatment 
or for relapsed/refractory cases may negatively affect 
survival.26 
No significant correlations were noted between 
survival rates and selected sociodemographic, clinical 
or laboratory characteristics in the present study. 
These findings partially agree with those previously 
reported by Shvidel et al.; however, they contradict 
de Faria et al.’s study.27,28 The difference between 
these findings is probably due to variations in sample 
size, the lack of genetic assessment conducted in the 
current study and the well-known impact of ethnicity.13 
In addition, data regarding CD49d and ZAP70 expression, 
which have a major prognostic impact on CLL 
patients, were not available.8 Further research is 
therefore recommended to evaluate these factors.
Conclusion 
The median age, male-to-female ratio and clinical and 
immunophenotypic characteristics of Iraqi CLL patients 
in the current study did not differ greatly from previous 
regional and international data; however, patients more 
frequently presented at an advanced stage and had a 
lower five-year OS rate compared to Western populations. 
In addition, Iraqi patients more frequently presented 
with organomegaly, including hepatomegaly, although 
less frequently with lymphadenopathy.
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